Summary
- NASDAQ announced its decision to delist WINDTREE THERAPEUTICS.
- They reported that the delisting was due to the failure to meet the requirement of maintaining a closing price of at least $1 per share.
- WINDTREE was noted as a company that had announced plans to invest in various virtual assets, including BNB.
NASDAQ has decided to delist WINDTREE THERAPEUTICS (ticker: WINT), a U.S. biopharmaceutical company that acts as a financial enterprise for Binance Coin (BNB).
According to a disclosure from the U.S. Securities and Exchange Commission (SEC) cited by The Block on the 20th (local time), WINDTREE THERAPEUTICS consistently failed to meet NASDAQ listing rule 5550(a)(2), which requires maintaining a minimum closing price of $1 per share. As a result, NASDAQ will suspend trading of this stock at the opening of the market on the 21st.
Meanwhile, WINDTREE is classified as one of the 'Digital Asset Treasury (DAT)' companies that have recently begun investing in various virtual assets (cryptocurrencies). In July, it entered into a $20 million stock purchase agreement with Build and Build, announcing its plans for a large-scale investment in BNB.
Suehyeon Lee
shlee@bloomingbit.ioI'm reporter Suehyeon Lee, your Web3 Moderator.
![[Analysis] "XRP risks repeating the 2022 rout…most short-term investors in the red"](https://media.bloomingbit.io/PROD/news/845f37bb-29b4-4bc5-9e10-8cafe305a92f.webp?w=250)
![[Exclusive] “Airdrops also taxable”... Authorities to adopt a ‘comprehensive approach’ to virtual assets](https://media.bloomingbit.io/PROD/news/4bde9dab-09bd-4214-a61e-f6dbf5aacdfb.webp?w=250)